

# APOLLO HOSPITALS ENTERPRISE LIMITED



14<sup>th</sup> November 2019 : L85110TN1979PLC008035

The Secretary,  
Bombay Stock Exchange Ltd (BSE)  
Phiroze Jheejheebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.  
**Scrip Code - 508869**  
**ISIN INE437A01024**

The Secretary,  
National Stock Exchange,  
Exchange Plaza, 5th Floor  
Plot No.C/1, 'G' Block  
Bandra - Kurla Complex  
Bandra (E)  
Mumbai - 400 051.  
**Scrip Code-**  
**APOLLOHOSP**  
**ISIN INE437A01024**

The Manager  
The National Stock  
Exchange,  
Wholesale Debt Market  
Exchange Plaza, 5th Floor  
Plot No.C/1, 'G' Block  
Bandra - Kurla Complex  
Bandra (E)  
Mumbai - 400 051.  
**ISIN INE437A07062,**  
**INE437A07070,**  
**INE437A07088 &**  
**INE437A07093**

Dear Sir,

## **Sub: Decisions at the Board Meeting held on 14<sup>th</sup> November 2019**

Further to our letter dated 25<sup>th</sup> September 2019, the Board of Directors at the meeting held on 14<sup>th</sup> November 2019 have approved the unaudited financial results of the Company for the quarter and half year ended 30<sup>th</sup> September 2019.

As required by the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, (LODR) we enclose/furnish the following particulars.

### **I. Financial Results**

1. Unaudited financial results (both standalone and consolidated) of the Company for the quarter and half year ended 30<sup>th</sup> September 2019, which have been subjected to Limited Review by the Statutory Auditors of the Company.
2. Copy of the Limited Review Report of the Statutory Auditors for the corresponding period.
3. The financial results will also be published in the newspapers, in the format prescribed under Regulation 47 of the Listing Regulations.
4. The said documents are being posted on the website of the Company i.e., [www.apollohospitals.com](http://www.apollohospitals.com).

IS/ISO 9001:2000

**Regd. Office :**  
19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

**General Office :**  
"Ali Towers", III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681  
Telefax : 044 - 2829 0956  
Email : [apolloshares@vsnl.net](mailto:apolloshares@vsnl.net)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

# APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



## II. Schedule of Conference Call

Pursuant to Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a conference call for the analysts/investors is scheduled to be held on Friday, 15<sup>th</sup> November 2019 at 12.30 p.m, to discuss the financial results for the quarter and half year ended 30<sup>th</sup> September 2019.

The meeting of the Board of Directors commenced at 11.00 a.m. and concluded at 2:45 p.m.

Please take note of the above in your records.

Thanking you,

Yours faithfully,  
For APOLLO HOSPITALS ENTERPRISE LIMITED

  
S.M. KRISHNAN  
VICE PRESIDENT - FINANCE  
AND COMPANY SECRETARY

CC : The Secretary,  
Luxembourg Stock Exchange,  
B.P. 165,  
L-2011 Luxembourg.

Ref : **ISIN US0376081065 - Rule 144a GDR**  
**ISIN US0376082055 - Reg. S GDR**

Securities and Exchange  
Commission  
Division of Corporation Finance  
Office of International Corporate  
Finance  
450 Fifth Street, N.W.  
Washington, D.C  
20549-0302  
File No. 82-34893

IS/ISO 9001:2000

**Regd. Office :**  
19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

**General Office :**  
"Ali Towers", III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681  
Telefax : 044 - 2829 0956  
Email : [apolloshares@vsnl.net](mailto:apolloshares@vsnl.net)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

Statement of Unaudited Consolidated Financial Results for the three months and six months ended September 30, 2019

(Rs. in lakhs)

Particulars	Three months ended 30/09/2019	Preceding Three months ended 30/06/2019	Corresponding Three months ended 30/09/2018	Year to date figures for current period ended 30/09/2019	Year to date figures for previous period ended 30/09/2018	Previous year ended 31/03/2019
	Unaudited	Unaudited	Refer Note 2	Unaudited	Refer Note 2	Audited
<b>1 Income</b>						
(a) Revenue from Operators	2,84,074	2,57,189	2,41,242	5,41,263	4,62,290	9,61,744
(b) Other Income	350	986	255	1,336	719	3,144
<b>Total Income (a + b)</b>	<b>2,84,424</b>	<b>2,58,175</b>	<b>2,41,497</b>	<b>5,42,599</b>	<b>4,63,009</b>	<b>9,64,888</b>
<b>2 Expenses</b>						
(a) Cost of Materials Consumed	47,099	42,872	41,942	89,971	80,324	1,64,488
(b) Purchases of Stock-in-Trade	93,279	83,735	76,946	1,77,014	1,52,570	3,08,755
(c) Changes in inventories of stock-in-trade	(3,091)	(2,831)	(1,506)	(5,922)	(7,684)	(7,156)
(d) Employee Benefits Expense	46,865	43,341	38,776	90,206	75,453	1,59,824
(e) Finance Costs	13,434	12,577	8,099	26,011	15,718	32,702
(f) Depreciation and amortisation expense	15,451	14,401	9,713	29,852	19,222	39,553
(g) Other Expenses	58,574	53,700	57,831	1,12,274	1,11,128	2,29,487
<b>Total Expenses</b>	<b>2,71,611</b>	<b>2,47,795</b>	<b>2,31,801</b>	<b>5,19,406</b>	<b>4,46,731</b>	<b>9,27,633</b>
<b>3 Profit before share of profit in associates / joint ventures and exceptional items (1) - (2)</b>	<b>12,813</b>	<b>10,380</b>	<b>9,696</b>	<b>23,193</b>	<b>16,278</b>	<b>37,255</b>
4 Share of profit of associates / joint ventures	552	(940)	(104)	(388)	(416)	98
<b>5 Profit before exceptional item and tax (3) + (4)</b>	<b>13,365</b>	<b>9,440</b>	<b>9,592</b>	<b>22,805</b>	<b>15,862</b>	<b>37,353</b>
6 Exceptional item	-	-	-	-	-	-
<b>7 Profit before tax (5) + (6)</b>	<b>13,365</b>	<b>9,440</b>	<b>9,592</b>	<b>22,805</b>	<b>15,862</b>	<b>37,353</b>
<b>8 Tax Expenses</b>						
Current Tax	6,131	6,085	3,320	12,216	6,064	12,588
Deferred Tax	(1,076)	(1,560)	861	(2,636)	2,051	4,749
<b>9 Profit for the year (7) - (8)</b>	<b>8,310</b>	<b>4,915</b>	<b>5,411</b>	<b>13,225</b>	<b>7,747</b>	<b>20,016</b>
<b>10 Other Comprehensive Income</b>						
Items that will not be reclassified to Profit or Loss						
Remeasurement gains / (losses) on defined benefit plan	(727)	211	(1,637)	(516)	(3,414)	(4,457)
Equity instruments through other comprehensive income	-	-	-	-	-	(28)
Tax on above	179	(72)	519	107	1,054	1,573
<b>Total Other Comprehensive Loss</b>	<b>(548)</b>	<b>139</b>	<b>(1,118)</b>	<b>(409)</b>	<b>(2,360)</b>	<b>(2,912)</b>
<b>11 Total Comprehensive Income for the year (after tax) (9) + (10)</b>	<b>7,762</b>	<b>5,054</b>	<b>4,293</b>	<b>12,816</b>	<b>5,387</b>	<b>17,104</b>
<b>Profit for the year attributable to:</b>						
Owners of the parent	8,624	5,720	6,341	14,344	9,737	23,604
Non-controlling interest	(314)	(805)	(930)	(1,119)	(1,990)	(3,588)
<b>Other Comprehensive Loss for the year attributable to:</b>						
Owners of the parent	(353)	139	(1,117)	(214)	(2,359)	(2,919)
Non-controlling interest	(195)	-	(1)	(195)	(1)	7
<b>Total Comprehensive Income for the year attributable to:</b>						
Owners of the parent	8,271	5,859	5,224	14,130	7,378	20,685
Non-controlling interest	(509)	(805)	(931)	(1,314)	(1,991)	(3,581)
<b>12 Paid-up equity share capital (Face value Rs.5/- per share)</b>						6,956
<b>Reserves (excluding Revaluation Reserves)</b>						3,25,611
<b>13 Earnings per equity share of Rs.5/- each</b>						
Basic and Diluted EPS before extraordinary items for the period (Rs.)	*6.20	*4.11	*4.56	*10.31	*7.00	*6.97
Basic and Diluted EPS after extraordinary items for the period (Rs.)	*6.20	*4.11	*4.56	*10.31	*7.00	*6.97

\*Not annualised



For APOLLO HOSPITALS ENTERPRISE LTD.

*Suneeta Reddy*  
Suneeta Reddy  
Managing Director



**Apollo Hospitals Enterprise Limited**  
 Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu  
**Consolidated Segment wise Revenue, Results, Segment Assets and Segment Liabilities**

(Rs. In lakhs)

Particulars	Three months ended 30/09/2019	Preceeding Three months ended 30/06/2019	Corresponding Three months ended 30/09/2018	Year to date figures for current period ended 30/09/2019	Year to date figures for previous period ended 30/09/2018	Current year ended 31/03/2019
	Unaudited	Unaudited	Refer Note 2	Unaudited	Refer Note 2	Audited
<b>1. Segment Revenue</b>						
a) Healthcare Services	1,49,272	1,35,855	1,30,336	2,85,127	2,49,393	5,16,184
b) Pharmacy	1,17,266	1,05,684	96,371	2,22,950	1,85,578	3,88,604
c) Clinics	18,146	16,220	14,927	34,366	28,148	58,875
d) Others	109	108	100	217	199	397
<b>SUB - TOTAL</b>	<b>2,84,793</b>	<b>2,57,867</b>	<b>2,41,734</b>	<b>5,42,660</b>	<b>4,63,318</b>	<b>9,64,060</b>
Less : Intersegmental Revenue	719	678	492	1,397	1,028	2,316
<b>Income from Operations</b>	<b>2,84,074</b>	<b>2,57,189</b>	<b>2,41,242</b>	<b>5,41,263</b>	<b>4,62,290</b>	<b>9,61,744</b>
<b>2. Segment Results</b>						
a) Healthcare Services	19,354	17,321	15,880	36,675	29,599	61,977
b) Pharmacy	7,083	5,839	4,205	12,922	7,533	16,817
c) Clinics	(381)	(1,138)	(2,559)	(1,519)	(5,751)	(11,490)
d) Others	(159)	(51)	14	(210)	(104)	(490)
<b>SUB - TOTAL</b>	<b>25,897</b>	<b>21,971</b>	<b>17,540</b>	<b>47,868</b>	<b>31,277</b>	<b>66,814</b>
Less : Finance Cost	13,434	12,577	8,099	26,011	15,718	32,702
Add : Other un-allocable income (net of expenditure)	350	986	255	1,336	719	3,144
<b>Profit Before Tax</b>	<b>12,813</b>	<b>10,380</b>	<b>9,696</b>	<b>23,193</b>	<b>16,278</b>	<b>37,256</b>
<b>3. Capital employed</b>						
<b>a) Healthcare Services *</b>						
Segment Assets	7,52,393	7,42,719	6,67,244	7,52,393	6,67,244	6,77,776
Segment Liabilities	(2,28,654)	(2,23,700)	(1,38,288)	(2,28,654)	(1,38,288)	(1,40,314)
<b>b) Pharmacy</b>						
Segment Assets	1,86,694	1,77,970	1,08,604	1,86,694	1,08,604	1,12,335
Segment Liabilities	(97,277)	(94,660)	(23,232)	(97,277)	(23,232)	(22,497)
<b>c) Clinics</b>						
Segment Assets	79,648	80,948	52,230	79,648	52,230	45,805
Segment Liabilities	(61,120)	(59,987)	(17,640)	(61,120)	(17,640)	(16,926)
<b>d) Others</b>						
Segment Assets	4,799	4,822	5,578	4,799	5,578	5,053
Segment Liabilities	(1,800)	(1,779)	(1,754)	(1,800)	(1,754)	(1,765)
<b>e) Unallocated</b>						
Assets	96,312	77,696	77,770	96,312	77,770	77,342
Liabilities	(4,25,266)	(3,95,973)	(4,08,364)	(4,25,266)	(4,08,364)	(4,03,466)
<b>Total</b>	<b>3,05,729</b>	<b>3,08,056</b>	<b>3,22,148</b>	<b>3,05,729</b>	<b>3,22,148</b>	<b>3,33,343</b>
* Includes Capital employed in various hospital projects under construction	46,846	81,576	80,553	46,846	80,553	82,177



For APOLLO HOSPITALS ENTERPRISE LTD.

Suneeta  
Managing Director

**Apollo Hospitals Enterprise Limited**  
**Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram,**  
**Chennai - 28, Tamil Nadu**

**Consolidated Balance Sheet**

Particulars	(Rs. in lakhs)	
	As at 30/09/2019 Unaudited	As at 31/03/2019 Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, Plant and Equipment	4,96,717	4,59,379
(b) Right Of Use Asset	1,60,353	-
(c) Capital work-in-progress	46,846	82,177
(d) Investment Property	623	654
(e) Goodwill	34,621	34,619
(f) Other Intangible assets	3,821	3,508
(g) Financial Assets		
(i) Investments in Equity accounted investee	32,760	36,544
(ii) Investments	3,122	2,759
(iii) Loans	1,844	1,080
(iv) Other financial assets	21,222	23,507
(h) Deferred tax assets	5,323	1,739
(i) Tax assets	27,488	25,395
(j) Other non-current assets	10,194	18,795
<b>Total non - current assets</b>	<b>8,44,934</b>	<b>6,90,156</b>
<b>Current assets</b>		
(a) Inventories	65,029	58,478
(b) Financial assets		
(i) Investments	8,177	6,865
(ii) Trade receivables	1,12,450	1,02,320
(iii) Cash and cash equivalents	33,746	28,273
(iv) Bank balances other than (iii) above	15,435	6,423
(v) Other financial assets	17,470	12,870
(vi) Loans	800	800
(c) Other current assets	15,240	12,126
	<b>2,68,347</b>	<b>2,28,155</b>
Asset classified as Held for Sale (Refer Note 7)	6,566	-
<b>Total current assets</b>	<b>2,74,913</b>	<b>2,28,155</b>
<b>Total Assets</b>	<b>11,19,847</b>	<b>9,18,311</b>



For APOLLO HOSPITALS ENTERPRISE LTD.

*Suneeta Reddy*  
**Suneeta Reddy**  
**Managing Director**

**Apollo Hospitals Enterprise Limited**  
**Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram,**  
**Chennai - 28, Tamil Nadu**

**Consolidated Balance Sheet**

(Rs. in lakhs)

Particulars	As at 30/09/2019	As at 31/03/2019
	Unaudited	Audited
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	6,956	6,956
(b) Other Equity	2,98,773	3,26,387
(c) Non-controlling Interests	13,042	13,546
<b>Total Equity</b>	<b>3,18,771</b>	<b>3,46,889</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	2,85,533	2,95,213
(ii) Other financial liabilities	2,36,124	47,737
(b) Provisions	1,420	1,144
(c) Deferred tax liabilities	24,137	31,486
(d) Other non-current liabilities	21	297
<b>Total Non - Current Liabilities</b>	<b>5,47,235</b>	<b>3,75,877</b>
<b>Current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	64,740	49,816
(ii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises; and	887	1,024
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	78,080	70,295
(iii) Other financial liabilities	84,715	49,608
(b) Other current liabilities	15,988	14,477
(c) Provisions	9,327	10,219
(d) Current Tax Liabilities	104	106
<b>Total Current Liabilities</b>	<b>2,53,841</b>	<b>1,95,545</b>
<b>Total Liabilities</b>	<b>8,01,076</b>	<b>5,71,422</b>
<b>Total Equity and Liabilities</b>	<b>11,19,847</b>	<b>9,18,311</b>



For APOLLO HOSPITALS ENTERPRISE LTD.

*Suneeta Reddy*  
**Suneeta Reddy**  
 Managing Director

**Apollo Hospitals Enterprise Limited**  
**Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu**

**Unaudited Consolidated Cashflow Information**

(Rs. in lakhs)

Particulars	Year to date figures for current period ended 30/09/2019	Year to date figures for previous period ended 30/09/2018
	Unaudited	Refer Note 2
<b>Cash flow from Operating Activities</b>		
Profit after tax	13,226	7,748
<b>Adjustments for:</b>		
Income tax expenses	9,580	8,114
Profit before tax	22,806	15,862
Operating Profit before working capital changes	81,336	54,964
<b>Net cash generated from operating activities (A)</b>	<b>36,267</b>	<b>40,753</b>
<b>Net cash generated from / (used in) Investing Activities (B)</b>	<b>(16,973)</b>	<b>(47,392)</b>
<b>Net cash generated from / (used in) Financing Activities (C)</b>	<b>(14,169)</b>	<b>5,098</b>
<b>Net Increase in cash and cash equivalents (A+B+C) = (D)</b>	<b>5,125</b>	<b>(1,541)</b>
Cash and cash equivalents at the beginning of the period (E)	28,621	30,633
Cash and cash equivalents at the end of the period (D) +(E)	33,746	29,092



For APOLLO HOSPITALS ENTERPRISE LTD.

*Suneeta Reddy*  
Suneeta Reddy  
Managing Director



**NOTES:**

1. The unaudited consolidated financial results of Apollo Hospitals Enterprise Limited ('the Company') and its subsidiaries (referred to as "Group") and its share of profit/loss of its associates and joint ventures, for the three and six months ended September 30, 2019 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 13, 2019 and November 14, 2019 respectively and have been subjected to limited review by the statutory auditors.
2. The consolidated results for the three months and six months ended September 30, 2018 and the consolidated statement of cash flow for the six months ended September 30, 2018, are approved by the Company's Board of Directors but have not been subjected to limited review by the statutory auditors.
3. The listed non-convertible debentures of the Company aggregating to Rs.50,000 lakhs as on September 30, 2019 are secured by way of first charge on the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
4. The Company's debt instruments was assigned a rating of AA by CRISIL indicating a high degree of safety.
5. Details of Secured Non Convertible Debentures of the Company are as follows :

Sr.No	Particulars	Previous Due Date (April 1, 2019 to September 30, 2019)		Next Due Date (October 1, 2019 to March 31, 2020)	
		Principal	Interest	Principal	Interest
1	2000 Secured Redeemable Non Convertible Debentures of Rs. 10 lakhs each	-	August 22, 2019 **	-	-
2	3000 Secured Redeemable Non Convertible Debentures of Rs. 10 lakhs each	-	-	-	October 7, 2019
3	2000 Secured Redeemable Non Convertible Debentures of Rs. 10 lakhs each	-	-	-	March 7, 2020

Interest has been paid on the due dates

\*\* The debentures were redeemed fully on August 22, 2019 upon exercise of call option by the Company.

6. The Company's Board of Directors at its meeting held on November 14, 2018 had approved a Scheme of Arrangement ("the Scheme") between Apollo Hospitals Enterprise Limited ("AHEL") and Apollo Pharmacies Limited ("APL") and their respective shareholders in accordance with the provisions of Sections 230 to 232 of the Companies Act, 2013, for the transfer of the front-end retail pharmacy business ("the disposal group") carried out in the standalone pharmacy segment to APL by way of slump sale, subject to necessary approvals by stock exchanges,



For APOLLO HOSPITALS ENTERPRISE LTD.  
*Suneeta Reddy*  
 Suneeta Reddy  
 Managing Director



shareholders, National Company Law Tribunal and all other requisite regulatory authorities.

The Company received no objection letters from National Stock Exchange of India Limited and BSE Limited. Further, the Company obtained approvals from Competition Commission of India (CCI) and from the equity shareholders in October 2019. The disposal group has not been classified as held for sale as at September 30, 2019, as the criteria for classification as held for sale as per Indian Accounting Standard (IND AS) 105 *Non-Current Assets Held for Sale and Discontinued Operations* was met subsequent to the quarter ended September 30, 2019. The Scheme would become effective upon filing of the Scheme, as sanctioned by the NCLT, with the Registrar of Companies.


7. The Board of Directors of the Company approved the sale of investments in an associate, Apollo Munich Health Insurance Company Limited (AMHI) to Housing Development Finance Corporation Limited for a cash consideration of Rs. 26,152 lakhs (subject to indemnity related and other contractually agreed deductions) and Rs.3,822 lakhs from Munich Health Holding AG towards joint venture termination fee. The sale is subject to meeting closing conditions, which includes obtaining regulatory approvals from Insurance Regulatory and Development Authority of India (IRDA), Competition Commission of India (CCI) and National Housing Bank (NHB).

The Company has obtained approval from Competition Commission of India (CCI) and as per the requirement of the Share Purchase Agreement dated June 19, 2019, made an additional investment of Rs. 3,163 lakhs by way of subscription to AMHI's rights issue. The actions required to complete the sale are in advanced stages of completion with approvals from IRDA and NHB expected shortly. The Company has assessed the criteria for classification of investments in associate AHMI as held for sale has been met as at September 30, 2019 under Indian Accounting Standard (IND AS) 105, *Non-Current Assets Held for Sale and Discontinued Operations* and accordingly, such investment is carried at lower of carrying amount and fair value less costs to sell. The Company has ceased to apply the equity method accounting on such investment in associate and consequently Company's share of loss of Rs.1,499 lakhs in AHMI has not been recognized in the statement of consolidated financial results for the three months ended September 30, 2019.

8. Effective April 1, 2019, the Group adopted Ind AS 116 "Leases", applied to lease contracts existing as on the said date, using the modified retrospective method, except for two lease arrangements for which the modified prospective approach has been used. Under the modified retrospective method, the cumulative effect of initial application is recognised in retained earnings at April 1, 2019.

On transition to Ind AS 116, the Group recognised right-of-use assets amounting to Rs. 159,208 lakhs (net of related accumulated depreciation), lease liabilities amounting to Rs. 190,524 lakhs and Rs. 30,546 lakhs in retained earnings (net of deferred tax) as at April 1, 2019. The Group has discounted lease payments using the applicable incremental borrowing rate as at April 1, 2019 for measuring the lease liability.

During the three and six months ended September 30, 2019, the Group has recognized interest expense on lease liabilities amounting to Rs. 4,180 lakhs and Rs. 8,330 lakhs and depreciation on right-of-use asset amounting to Rs. 4,839



For APOLLO HOSPITALS ENTERPRISE LTD.

Suneeta Reddy  
Managing Director

lakhs and Rs. 9,617 lakhs respectively. The effect of applying this standard resulted in reduction of profit by Rs. 1,634 lakhs and Rs. 3,307 lakhs for the three months and six months ended September 30, 2019.

9. The proceedings initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company, by the Government of Karnataka alleging, non-compliance of certain conditions associated with the allotment of land, has been stayed by the Honourable High Court of Karnataka on April 27, 2018. Based on legal opinion, the management is of the opinion that it has adequate grounds to demonstrate compliance with applicable conditions and therefore the proceedings are not sustainable. There have been no further developments during this quarter.
10. The aforesaid financial results are also available on the Company's website ([www.apollohospitals.com](http://www.apollohospitals.com)).

For APOLLO HOSPITALS ENTERPRISE LIMITED

Place: Chennai  
Date: November 14, 2019

Dr. Prathap C Reddy  
Executive Chairman



For APOLLO HOSPITALS ENTERPRISE LTD.

Suneeta Reddy  
Managing Director



Apollo Hospitals Enterprise Limited  
Corporate Identity Number : L85110TN1979PLC008035  
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com  
Website: www.apollohospitals.com

Statement of Unaudited Standalone Financial Results for the three months and six months ended September 30, 2019

Particulars	(Rs. in lakhs)					
	Three months ended 30/09/2019	Preceeding Three months ended 30/06/2019	Corresponding Three months ended 30/09/2018	Year to date figures for current period ended 30/09/2019	Year to date figures for previous period ended 30/09/2018	Previous year ended 31/03/2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1 Income</b>						
(a) Revenue from Operations	2,46,358	2,22,920	2,09,012	4,69,278	4,00,051	8,33,666
(b) Other Income	394	474	(7)	868	198	1,224
<b>Total Income</b>	<b>2,46,752</b>	<b>2,23,394</b>	<b>2,09,005</b>	<b>4,70,146</b>	<b>4,00,249</b>	<b>8,34,890</b>
<b>2 Expenses</b>						
(a) Cost of Materials Consumed	39,802	36,470	35,540	76,272	67,962	1,39,168
(b) Purchase of Stock-in-Trade	92,491	82,643	76,026	1,75,134	1,50,757	3,04,930
(c) Changes in inventories of stock-in-trade	(3,132)	(2,803)	(1,493)	(5,935)	(7,726)	(7,200)
(d) Employee Benefits Expense	38,094	35,284	31,139	73,378	60,725	1,29,509
(e) Finance Costs	10,769	9,991	6,602	20,760	12,809	26,802
(f) Depreciation and amortisation expense	12,032	10,981	7,388	23,013	14,628	29,989
(g) Other Expenses	42,661	38,746	42,019	81,407	79,887	1,65,445
<b>Total Expenses</b>	<b>2,32,717</b>	<b>2,11,312</b>	<b>1,97,221</b>	<b>4,44,029</b>	<b>3,79,042</b>	<b>7,88,643</b>
3 Profit before exceptional item and tax (1) - (2)	14,035	12,082	11,784	26,117	21,207	46,247
4 Exceptional Items	-	-	-	-	-	-
5 Profit before tax (3) - (4)	14,035	12,082	11,784	26,117	21,207	46,247
<b>6 Tax Expenses</b>						
Current Tax	5,820	5,722	2,998	11,542	5,404	11,120
Deferred Tax	(845)	(1,571)	888	(2,416)	1,888	4,851
7 Profit for the period / year (5) - (6)	9,060	7,931	7,898	16,991	13,915	30,276
<b>8 Other Comprehensive Income</b>						
Items that will not be reclassified to Profit and Loss						
-Remeasurement gains/(losses) on defined benefit plan	(48)	207	(1,484)	160	(3,017)	(4,453)
-Tax on above	17	(72)	519	(56)	1,054	1,541
Other Comprehensive Income / (Loss)	(31)	135	(965)	104	(1,963)	(2,912)
9 Total Comprehensive Income for the period / year (after tax) (7) + (8)	9,029	8,066	6,933	17,095	11,952	27,364



For APOLLO HOSPITALS ENTERPRISE LTD.

Suneeta Reddy  
Managing Director



Apollo Hospitals Enterprise Limited  
Corporate Identity Number : L85110TN1979PLC008035  
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com  
Website: www.apollohospitals.com

Statement of Unaudited Standalone Financial Results for the three months and six months ended September 30, 2019

Particulars	Three months ended 30/09/2019	Preceeding Three months ended 30/06/2019	Corresponding Three months ended 30/09/2018	Year to date figures for current period ended 30/09/2019	Year to date figures for previous period ended 30/09/2018	Previous year ended 31/03/2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
10 Paid-up equity share capital (Face value Rs.5/- per share)						6,956
11 Reserves (excluding Revaluation Reserves)						3,81,384
12 Net Worth (Refer footnote 1)				3,52,858	3,54,647	3,70,057
13 Paid up Debt Capital				50,000	70,000	70,000
14 Debenture Redemption Reserve				17,500	17,500	17,500
15 Capital Redemption Reserve				600	600	600
16 Earnings per equity share of Rs.5/- each						
Basic and Diluted EPS before extraordinary items for the period (Rs.)	*6.51	*5.70	*5.68	*12.21	*10.00	21.76
Basic and Diluted EPS after extraordinary items for the period (Rs.)	*6.51	*5.70	*5.68	*12.21	*10.00	21.76
Debt Equity Ratio (Refer footnote 2)				0.96	0.91	0.88
Debt Service Coverage Ratio (DSCR) (Refer footnote 3)				2.53	2.42	2.45
Interest Service Coverage Ratio (ISCR) (Refer footnote 4)				5.82	4.04	4.24
<b>Additional Information :-</b>						
Earnings before finance costs, tax, depreciation and amortization, exceptional items (EBITDA) (Refer footnote 5)	36,442	32,580	25,781	69,022	48,446	1,01,814

\*Not annualised

**Foot Notes:**

- 1 Networth = Equity Share Capital + Other Equity excluding Capital Reserves, Capital Redemption Reserve and Debenture Redemption Reserve
- 2 Debt Equity Ratio  
Debt = Long Term Borrowings + Short Term Borrowings + Current Maturities of Long Term Borrowings  
Equity = Paid up capital + Other equity excluding Capital Reserve, Capital Redemption Reserve and Debenture Redemption Reserve
- 3 Debt Service Coverage Ratio = Profit before interest, depreciation and tax / Interest on loans + Repayment of long term loans during the period
- 4 Interest Service Coverage Ratio = Profit before depreciation, interest on long term loans and tax / Interest on long term loans
- 5 The company has presented Earnings before Finance costs, Tax, Depreciation, Amortization, Other income and Exceptional items (EBITDA) additionally as part of Financial Results.



For APOLLO HOSPITALS ENTERPRISE LTD.


*Suneeta Reddy*  
**Suneeta Reddy**  
Managing Director

**Apollo Hospitals Enterprise Limited**  
 Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu

**Segment wise Revenue, Results, Segment Assets and Segment Liabilities**

(Rs. In lakhs)

Particulars	Three months ended 30/09/2019	Preceeding Three months ended 30/06/2019	Corresponding Three months ended 30/09/2018	Year to date figures for current period ended 30/09/2019	Year to date figures for previous period ended 30/09/2018	Current year ended 31/03/2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Segment Revenue</b>						
<b>Total Income from operations, Net</b>						
a) Healthcare Services	1,29,118	1,17,258	1,12,661	2,46,376	2,14,516	4,45,141
b) Pharmacy	1,17,266	1,05,684	96,370	2,22,950	1,85,577	3,88,604
<b>SUB - TOTAL</b>	<b>2,46,384</b>	<b>2,22,942</b>	<b>2,09,031</b>	<b>4,69,326</b>	<b>4,00,093</b>	<b>8,33,745</b>
Less : Intersegmental Revenue	26	22	19	48	42	79
<b>Income from Operations</b>	<b>2,46,358</b>	<b>2,22,920</b>	<b>2,09,012</b>	<b>4,69,278</b>	<b>4,00,051</b>	<b>8,33,666</b>
<b>2. Segment Results</b>						
a) Healthcare Services	17,325	15,760	14,188	33,087	26,285	55,008
b) Pharmacy	7,083	5,839	4,205	12,922	7,533	16,817
<b>SUB - TOTAL</b>	<b>24,410</b>	<b>21,599</b>	<b>18,393</b>	<b>46,009</b>	<b>33,818</b>	<b>71,825</b>
Less : Finance Cost	10,769	9,991	6,602	20,760	12,809	26,802
Add : Other un-allocable income (net of expenditure)	394	474	(7)	868	198	1,224
<b>Profit Before Tax</b>	<b>14,035</b>	<b>12,082</b>	<b>11,784</b>	<b>26,117</b>	<b>21,207</b>	<b>46,247</b>
<b>3. Capital employed</b>						
<b>Segment assets-Segment liabilities</b>						
<b>a) Healthcare Services *</b>						
Segment Assets	6,65,863	6,57,178	5,86,248	6,65,863	5,86,248	6,00,009
Segment Liabilities	(1,53,772)	(1,49,448)	(76,371)	(1,53,772)	(76,371)	(73,480)
<b>b) Pharmacy</b>						
Segment Assets	1,86,694	1,77,970	1,08,604	1,86,694	1,08,604	1,12,335
Segment Liabilities	(97,277)	(94,660)	(23,232)	(97,277)	(23,232)	(22,497)
<b>c) Unallocated</b>						
Assets	1,46,860	1,32,973	1,39,217	1,46,860	1,39,217	1,30,502
Liabilities	(3,77,228)	(3,51,740)	(3,61,537)	(3,77,228)	(3,61,537)	(3,58,529)
<b>Total</b>	<b>3,71,140</b>	<b>3,72,273</b>	<b>3,72,929</b>	<b>3,71,140</b>	<b>3,72,929</b>	<b>3,88,340</b>
* Includes segment assets in various hospital projects under construction.	46,396	81,576	80,553	46,396	80,553	81,881



For APOLLO HOSPITALS ENTERPRISE LTD.

*Suneeta Reddy*  
 Suneeta Reddy  
 Managing Director

Apollo Hospitals Enterprise Limited  
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram,  
Chennai - 28, Tamil Nadu

Standalone Balance Sheet

(Rs. in lakhs)

Particulars	As at	As at
	30/09/2019	31/03/2019
	Unaudited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, Plant and Equipment	4,22,790	3,84,472
(b) Right of use assets	1,24,352	-
(c) Capital work-in-progress	46,396	81,881
(d) Goodwill	9,483	9,483
(e) Other Intangible assets	3,239	3,032
(f) Financial Assets		
(i) Investments	1,03,974	1,07,271
(ii) Loans	3,213	1,959
(iii) Other financial assets	18,110	21,123
(g) Tax Assets	19,545	17,395
(h) Other Non-Current Assets	7,752	15,927
<b>Total Non - Current Assets</b>	<b>7,58,854</b>	<b>6,42,543</b>
<b>Current assets</b>		
(a) Inventories	62,599	56,115
(b) Financial assets		
(i) Investments	3,624	1,257
(ii) Trade receivables	1,00,102	90,932
(iii) Cash and cash equivalents	25,221	21,896
(iv) Bank balances other than (iii) above	14,199	5,870
(v) Loans	800	800
(vi) Other financial assets	14,923	12,843
(d) Other current assets	12,344	10,590
	<b>2,33,812</b>	<b>2,00,303</b>
Asset classified as Held for Sale (Refer Note 7)	6,751	-
<b>Total Current Assets</b>	<b>2,40,563</b>	<b>2,00,303</b>
<b>Total Assets</b>	<b>9,99,417</b>	<b>8,42,846</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share capital	6,956	6,956
(b) Other Equity	3,64,184	3,81,384
<b>Equity attributable to owners of the Company</b>	<b>3,71,140</b>	<b>3,88,340</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	2,47,102	2,59,733
(ii) Other financial liabilities	1,47,095	415
(b) Deferred tax liabilities (Not)	23,745	31,037
<b>Total Non - Current Liabilities</b>	<b>4,17,942</b>	<b>2,91,185</b>
<b>Current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	59,860	45,569
(ii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises; and	681	818
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	56,796	52,838
(iii) Other financial liabilities	71,590	42,585
(b) Other current liabilities	13,033	11,907
(c) Provisions	8,375	9,604
<b>Total Current Liabilities</b>	<b>2,10,335</b>	<b>1,63,321</b>
<b>Total Liabilities</b>	<b>6,28,277</b>	<b>4,54,506</b>
<b>Total Equity and Liabilities</b>	<b>9,99,417</b>	<b>8,42,846</b>



For APOLLO HOSPITALS ENTERPRISE LTD.

*Suneeta Reddy*  
Suneeta Reddy  
Managing Director



**Apollo Hospitals Enterprise Limited**  
**Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu**

**Unaudited Standalone Cashflow Information**

(Rs. in lakhs)

Particulars	Year to date figures for current period ended 30/09/2019	Year to date figures for previous period ended 30/09/2018
	Unaudited	Refer Note 2
<b>Cash flow from Operating Activities</b>		
Profit after tax	16,991	13,915
<b>Adjustments for:</b>		
Income tax expenses	9,126	7,292
Profit before tax	26,117	21,207
Operating Profit before working capital changes	76,310	55,052
<b>Net cash generated from operating activities (A)</b>	<b>39,342</b>	<b>36,401</b>
<b>Net cash generated from / (used in) Investing Activities (B)</b>	<b>(26,731)</b>	<b>(47,813)</b>
<b>Net cash used in Financing Activities (C)</b>	<b>(9,286)</b>	<b>7,983</b>
<b>Net Increase in cash and cash equivalents (A+B+C) = (D)</b>	<b>3,325</b>	<b>(3,429)</b>
Cash and cash equivalents at the beginning of the period (E)	21,896	24,694
Cash and cash equivalents at the end of the period (D) +(E)	25,221	21,265



For APOLLO HOSPITALS ENTERPRISE LTD.

*Suneeta Reddy*  
**Suneeta Reddy**  
**Managing Director**

**NOTES:**

1. The unaudited standalone financial results of Apollo Hospitals Enterprise Limited ("the Company") for the three months and six months ended September 30, 2019 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 13, 2019 and November 14, 2019 respectively and have been subjected to limited review by the statutory auditors.
2. The standalone statement of cash flow for the six months ended September 30, 2018 are approved by the Company's Board of Directors but have not been subjected to limited review by the statutory auditors.
3. The listed non-convertible debentures of the Company aggregating to Rs. 50,000 lakhs as on September 30, 2019 are secured by way of first charge on the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
4. The Company's debt instruments was assigned a rating of AA by CRISIL indicating a high degree of safety.
5. Details of Secured Non Convertible Debentures are as follows :

Sr.No	Particulars	Previous Due Date (April 1, 2019 to September 30, 2019)		Next Due Date (October 1, 2019 to March 31, 2020)	
		Principal	Interest	Principal	Interest
1	2000 Secured Redeemable Non Convertible Debentures of Rs. 10 lakhs each	-	August 22, 2019 **	-	-
2	3000 Secured Redeemable Non Convertible Debentures of Rs. 10 lakhs each	-	-	-	October 7, 2019
3	2000 Secured Redeemable Non Convertible Debentures of Rs. 10 lakhs each	-	-	-	March 7, 2020

Interest has been paid on the due dates

\*\* The debentures were redeemed fully on August 22, 2019 upon exercise of call option by the Company.

6. The Board of Directors at their meeting held on November 14, 2018 had approved a Scheme of Arrangement ("the Scheme") between Apollo Hospitals Enterprise Limited ("AHEL") and Apollo Pharmacies Limited ("APL") and their respective shareholders in accordance with the provisions of Sections 230 to 232 of the Companies Act, 2013, for the transfer of the front-end retail pharmacy business



For APOLLO HOSPITALS ENTERPRISE LTD.

*Suneeta Reddy*  
Suneeta Reddy  
Managing Director



("the disposal group") carried out in the standalone pharmacy segment to APL by way of slump sale, subject to necessary approvals by stock exchanges, shareholders, National Company Law Tribunal and all other requisite regulatory authorities.

The Company received no objection letters from National Stock Exchange of India Limited and BSE Limited. Further, the Company obtained approvals from Competition Commission of India (CCI) and from the equity shareholders in October 2019. The disposal group has not been classified as held for sale as at September 30, 2019, as the criteria for classification as held for sale as per Indian Accounting Standard (IND AS) 105 *Non-Current Assets Held for Sale and Discontinued Operations* was met subsequent to the quarter ended September 30, 2019. The Scheme would become effective upon filing of the Scheme, as sanctioned by the NCLT, with the Registrar of Companies.

7. The Board of Directors of the Company approved the sale of investments in an associate, Apollo Munich Health Insurance Company Limited (AMHI) to Housing Development Finance Corporation Limited for a cash consideration of Rs. 26,152 lakhs (subject to indemnity related and other contractually agreed deductions) and Rs.3,822 lakhs from Munich Health Holding AG towards joint venture termination fee. The sale is subject to meeting closing conditions, which includes obtaining regulatory approvals from Insurance Regulatory and Development Authority of India (IRDA), Competition Commission of India (CCI) and National Housing Bank (NHB).

The Company has obtained approval from Competition Commission of India (CCI) and as per the requirement of the Share Purchase Agreement dated June 19, 2019, made an additional investment of Rs. 3,163 lakhs by way of subscription to AMHI's rights issue. The actions required to complete the sale are in advanced stages of completion with approvals from IRDA and NHB expected shortly. The Company has assessed the criteria for classification of investments in associate AHMI as held for sale has been met as at September 30, 2019 under Indian Accounting Standard (IND AS) 105, *Non-Current Assets Held for Sale and Discontinued Operations* and accordingly, such investment is carried at lower of carrying amount and fair value less costs to sell.

8. Effective April 1, 2019, the Company adopted Ind AS 116 "Leases", applied to all lease contracts existing as on the said date, using the modified retrospective method. Under this method, the cumulative effect of initial application is recognised in retained earnings at April 1, 2019.

On transition to Ind AS 116, the Company recognised right-of-use assets amounting to Rs. 120,539 lakhs (net of related accumulated depreciation), lease liabilities amounting to Rs. 141,926 lakhs and Rs. 24,193 lakhs (debit) in retained earnings (net of deferred tax) as at April 1, 2019. The Company has discounted lease payments using the applicable incremental borrowing rate as at April 1, 2019 for measuring the lease liability.

During the three and six months ended September 30, 2019, the Company has recognized interest expense on lease liabilities amounting to Rs. 3,122 lakhs &



For APOLLO HOSPITALS ENTERPRISE LTD.

  
Suneeta Reddy  
Managing Director



Rs.6,226 lakhs and depreciation on right-of-use asset amounting to Rs. 3,645 lakhs and Rs. 7,277 lakhs respectively. The effect of applying this standard resulted in reduction of profit by Rs. 1,326 lakhs and Rs. 2,703 lakhs for the three months and six months ended September 30, 2019, respectively.

9. The aforesaid financial results are also available on the Company's website ([www.apollohospitals.com](http://www.apollohospitals.com)).

For APOLLO HOSPITALS ENTERPRISE LIMITED

Place: Chennai  
Date: November 14, 2019

Dr. Prathap C Reddy  
Executive Chairman



For APOLLO HOSPITALS ENTERPRISE LTD.

  
Suneeta Reddy  
Managing Director

**Apollo Hospitals Enterprise Limited**  
**Corporate Identity Number : L85110TN1979PLC008035**  
**Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu**  
**Tel. +91-44-28290956, Fax.+91-44-28290956, Email: investor.relations@apollohospitals.com, Website : www.apollohospitals.com**  
**Extract of Statement of Unaudited Financial Results for the Three and Six Months Ended September 30, 2019**

(Rs. in Lakhs, except per share data)

Particulars	Standalone						Consolidated					
	Three months ended 30/09/2019	Preceding Three months ended 30/06/2019	Corresponding Three months ended 30/09/2019	Year to date figures for current period ended 30/09/2019	Year to date figures for previous period ended 30/09/2018	Previous year ended 31/03/2019	Three months ended 30/09/2019	Preceding Three months ended 30/06/2019	Corresponding Three months ended 30/09/2019	Year to date figures for current period ended 30/09/2019	Year to date figures for previous period ended 30/09/2018	Previous year ended 31/03/2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income from Operations (net)	2,46,752	2,23,394	2,09,005	4,70,146	4,00,249	8,34,890	2,84,424	2,58,175	2,41,497	5,42,599	4,63,009	9,64,888
Net Profit /(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	14,035	12,082	11,784	26,117	21,207	46,247	13,365	9,440	9,592	22,805	15,862	37,353
Net Profit /(Loss) for the period (before Tax, after Exceptional and/or Extraordinary Items)	14,035	12,082	11,784	26,117	21,207	46,247	13,365	9,440	9,594	22,805	15,861	37,353
Net profit /(Loss) for the period after tax (after Exceptional and Extraordinary items)	9,060	7,931	7,898	16,991	13,915	30,276	8,310	4,915	5,411	13,225	7,747	20,016
Total Comprehensive Income for the period (comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	9,029	8,066	6,933	17,095	11,952	27,364	7,762	5,054	4,293	12,816	5,387	17,104
Paid up Equity Share Capital (Face value of Rs.5/- each)	6,956	6,956	6,956	6,956	6,956	6,956	6,956	6,956	6,956	6,956	6,956	6,956
Other Equity						3,81,384						3,25,611
Earnings Per Share of Rs. 5/- each												
Basic	*6.51	*5.70	*5.68	*12.21	*10.00	21.76	*6.20	*4.11	*4.56	*10.31	*7.0	16.97
Diluted	*6.51	*5.70	*5.68	*12.21	*10.00	21.76	*6.20	*4.11	*4.56	*10.31	*7.0	16.97
Debt Equity Ratio				0.96	0.91	0.88						
Debt Service Coverage Ratio				2.53	2.42	2.45						
Interest Service Coverage Ratio				5.82	4.04	4.24						
Networth				3,52,858	3,54,647	3,70,057						
Paid up Debt Capital				50,000	70,000	70,000						
Debenture Redemption Reserve				17,500	17,500	17,500						
Capital Redemption Reserve				600	600	600						

\* Not Annualised

**Notes**

The above is an extract of the detailed format of financial results (both standalone and consolidated) for the three and six months ended September 30, 2019 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the stock exchange websites [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and also the company's website [www.apollohospitals.com](http://www.apollohospitals.com).





- 2 The unaudited standalone and consolidated financial results of Apollo Hospitals Enterprise Limited ("the Company") for the three and six months ended September 30, 2019 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 13 and November 14, 2019 respectively and have been subjected to limited review by the statutory auditors.
- 3 The standalone statement of cash flow for the six months ended September 30, 2018 are approved by the Company's Board of Directors but have not been subjected to limited review by the statutory auditors.
- 4 The consolidated results for the three months and six months ended September 30, 2018 and the consolidated statement of cash flow for the six months ended September 30, 2018, are approved by the Parent's Board of Directors but have not been subjected to limited review by the statutory auditors.
- 5 For the items referred in sub-clauses (a), (b), (d) and (e) of the Regulation 52(4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to the Stock Exchanges (BSE and NSE) and can be accessed on the URL ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com))
- 6 The listed non-convertible debentures of the Company aggregating to Rs. 50000 lakhs as on September 30, 2019 are secured by way of first charge on the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.

- The Board of Directors at their meeting held on November 14, 2018 had approved a Scheme of Arrangement ("the Scheme") between Apollo Hospitals Enterprise Limited ("AHEL") and Apollo Pharmacies Limited ("APL") and their respective shareholders in accordance with the provisions of Sections 230 to 232 of the Companies Act, 2013, for the transfer of the front-end retail pharmacy business ("the disposal group") carried out in the standalone pharmacy segment to APL by way of slump sale, subject to necessary approvals by stock exchanges, shareholders, National Company Law Tribunal and all other requisite regulatory authorities.
- 7 The Company received no objection letters from National Stock Exchange of India Limited and BSE Limited. Further, the Company obtained approvals from Competition Commission of India (CCI) and from the equity shareholders in October 2019. The disposal group has not been classified as held for sale as at September 30, 2019, as the criteria for classification as held for sale as per Indian Accounting Standard (IND AS) 105 Non-Current Assets Held for Sale and Discontinued Operations was met subsequent to the quarter ended September 30, 2019. The Scheme would become effective upon filing of the Scheme, as sanctioned by the NCLT, with the Registrar of Companies.

- The Board of Directors of the Company approved the sale of investments in an associate, Apollo Munich Health Insurance Company Limited (AMHI) to Housing Development Finance Corporation Limited for a cash consideration of Rs. 26,152 lakhs (subject to indemnity related and other contractually agreed deductions) and Rs.3,822 lakhs from Munich Health Holding AG towards joint venture termination fee. The sale is subject to meeting closing conditions, which includes obtaining regulatory approvals from Insurance Regulatory and Development Authority of India (IRDA), Competition Commission of India (CCI) and National Housing Bank (NHB).
- 8 The Company has obtained approval from Competition Commission of India (CCI) and as per the requirement of the Share Purchase Agreement dated June 19, 2019, made an additional investment of Rs. 3,163 lakhs by way of subscription to AMHI's rights issue. The actions required to complete the sale are in advanced stages of completion with approvals from IRDA and NHB expected shortly. The Company has assessed the criteria for classification of investments in associate AHMI as held for sale has been met as at September 30, 2019 under Indian Accounting Standard (IND AS) 105, Non-Current Assets Held for Sale and Discontinued Operations and accordingly, such investment is carried at lower of carrying amount and fair value less costs to sell.

9

**Standalone :-**

Effective April 1, 2019, the Company adopted Ind AS 116 "Leases", applied to all lease contracts existing as on the said date, using the modified retrospective method. Under this method, the cumulative effect of initial application is recognised in retained earnings at April 1, 2019.

On transition to Ind AS 116, the Company recognised right-of-use assets amounting to Rs. 120,539 lakhs (net of related accumulated depreciation), lease liabilities amounting to Rs. 141,926 lakhs and Rs. 24,193 lakhs (debit) in retained earnings (net of deferred tax) as at April 1, 2019. The Company has discounted lease payments using the applicable incremental borrowing rate as at April 1, 2019 for measuring the lease liability. During the three and six months ended September 30, 2019, the Company has recognized interest expense on lease liabilities amounting to Rs. 3,122 lakhs & Rs.6,226 lakhs and depreciation on right-of-use asset amounting to Rs. 3,645 lakhs and Rs. 7,277 lakhs respectively. The effect of applying this standard resulted in reduction of profit by Rs. 1,326 lakhs and Rs. 2,703 lakhs for the three months and six months ended September 30, 2019, respectively.





**Consolidated:-**

Effective April 1, 2019, the Group adopted Ind AS 116 "Leases", applied to lease contracts existing as on the said date, using the modified retrospective method, except for two lease arrangements for which the modified prospective approach has been used. Under the modified retrospective method, the cumulative effect of initial application is recognised in retained earnings at April 1, 2019.

On transition to Ind AS 116, the Group recognised right-of-use assets amounting to Rs. 159,208 lakhs (net of related accumulated depreciation), lease liabilities amounting to Rs. 190,524 lakhs and Rs. 30,546 lakhs in retained earnings (net of deferred tax) as at April 1, 2019. The Group has discounted lease payments using the applicable incremental borrowing rate as at April 1, 2019 for measuring the lease liability.

During the three and six months ended September 30, 2019, the Group has recognized interest expense on lease liabilities amounting to Rs. 4,180 lakhs and Rs. 8,330 lakhs and depreciation on right-of-use asset amounting to Rs. 4,839 lakhs and Rs. 9,617 lakhs respectively. The effect of applying this standard resulted in reduction of profit by Rs. 1,634 lakhs and Rs. 3,307 lakhs for the three months and six months ended September 30, 2019.

for APOLLO HOSPITALS ENTERPRISE LIMITED

Place : Chennai  
Date : 14th November 2019

DR. PRATHAP C REDDY  
Executive Chairman



## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

Tel: +91 22 6185 4000  
Fax: +91 22 6185 4001


### TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **APOLLO HOSPITALS ENTERPRISE LIMITED** ("the Company"), for the three months and six months ended September 30, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Attention is drawn to Note 2 of the Statement which states that the statement of cash flows for the corresponding six months ended September 30, 2018, as reported in the accompanying Statement have been approved by the Company's Board of Directors, but have not been subjected to review.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Vikas Bagaria  
(Partner)  
(Membership No. 060408)  
(UDIN: 19060408AAAABU6630)

Place: Mumbai  
Date: November 14, 2019



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF  
INTERIM CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
APOLLO HOSPITALS ENTERPRISE LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **APOLLO HOSPITALS ENTERPRISE LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit/(loss) after tax and total comprehensive loss of its associates and joint ventures for the three months and six months ended September 30, 2019 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Attention is drawn to Note 2 to the Statement which states that the consolidated figures for the corresponding three months ended



September 30, 2018 and the year to date figures for the previous period ended September 30, 2018 and the statement of consolidated cash flows for the corresponding six months ended September 30, 2018, as reported in the accompanying Statement have been approved by the Parent's Board of Directors, but have not been subjected to review.

4. The Statement includes the results of the following entities:

<b>Name of the Company</b>	<b>Relationship</b>
Apollo Hospitals Enterprise Limited	Parent
Apollo Home Healthcare (India) Limited	Subsidiary
Apollo Home Healthcare Limited	Subsidiary
AB Medical Centres Limited	Subsidiary
Samudra Health Care Enterprises Limited	Subsidiary
Imperial Hospitals & Research Centre Limited	Subsidiary
Apollo Hospitals (UK) Limited	Subsidiary
Apollo Health and Lifestyle Limited (AHLL)	Subsidiary
Alliance Dental Care Limited	Subsidiary of AHLL
Apollo Dialysis Private Limited	Subsidiary of AHLL
Apollo Sugar Clinics Limited	Subsidiary of AHLL
Apollo Speciality Hospitals Private Limited	Subsidiary of AHLL
AHLL Diagnostics Limited	Subsidiary of AHLL
AHLL Risk Management Private Limited	Subsidiary of AHLL
Apollo Bangalore Cradle Limited	Stepdown Subsidiary of AHLL
Kshema Healthcare Private Limited	Stepdown Subsidiary of AHLL
Apollo Nellore Hospital Limited	Subsidiary
Sapein Bio-sciences Private Limited	Subsidiary
Apollo Hospitals International Limited (AHIL)	Subsidiary
Apollo-Amrish Oncology Services Private Limited	Associate of AHIL
Apollo CVHF Limited	Subsidiary of AHIL
Western Hospitals Corporation Limited	Subsidiary
Apollo Lavasa Health Corporation Limited	Subsidiary
Apollo Rajshree Hospital private Limited	Subsidiary
Future Parking Private Limited	Subsidiary
Total Health	Subsidiary
Apollo Hospitals Singapore Pte Limited	Subsidiary
Assam Hospitals Limited	Subsidiary
Apollo Health Care Technologies Solution Limited	Subsidiary
Apollo Medical Private Limited (AMPL)	Subsidiary
Apollo Pharmacy Limited	Subsidiary of AMPL
Apollo Gleneagles Hospitals Limited	Joint venture
Apollo Gleneagles PET-CT private Limited	Joint venture
ApoKos Rehab Private limited	Joint venture
Medics International Lifesciences Limited	Joint Venture

2

Apollo Munich Health Insurance Company Limited	Associate
Family Health Plan Insurance (TPA) Limited	Associate
Indraprastha Medical Corporation Limited	Associate
Stemcyte India Therapeutics Private Limited	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 8 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We draw attention to Note 9 to the Statement in respect of proceedings initiated against the company's subsidiary, Imperial Hospital & Research Centre Limited, by the Government of Karnataka, as reported by the other auditors of the said subsidiary company. Our conclusion on the Statement is not modified in respect of this matter.
7. We did not review the financial results of 20 subsidiaries included in the consolidated unaudited financial results, whose financial results reflect total assets of Rs. 135,780 lakhs as at September 30, 2019, total revenues of Rs. 24,015 lakhs and Rs. 45,949 lakhs for the three months and six months ended September 30, 2019 respectively, total net profit after tax of Rs. 1,080 lakhs and Rs. 1,192 lakhs for the three months and six months ended September 30, 2019 respectively and total comprehensive income of Rs. 580 lakhs and Rs. 691 lakhs for the three months and six months ended September 30, 2019 respectively and net cash flows of Rs. 1,471 lakhs for the six months ended September 30, 2019, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of profit after tax of Rs. 395 lakhs and Rs. 277 lakhs for the three months and six months ended September 30, 2019 respectively and Total comprehensive income of Rs. 386 lakhs and Rs. 258 lakhs for the three months and six months ended September 30, 2019 respectively, as considered in the Statement, in respect of 2 joint ventures and 3 associates, whose financial results have not been reviewed by us. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.




Our conclusion on the Statement is not modified in respect of these matters.

8. The consolidated unaudited financial results includes the interim financial information of 7 subsidiaries which have not been reviewed by their auditors, whose interim financial information total assets of Rs.4,847 lakhs as at September 30,2019 and total revenue of Rs. 29 lakhs and Rs. 29 lakhs for the three months and six months ended September 30, 2019 respectively, total loss after tax (net) of Rs. 110 lakhs and Rs. 140 lakhs for the three months and six months ended September 30, 2019 respectively and Total comprehensive loss of Rs.110 lakhs and Rs. 140 lakhs for the three months and six months ended September 30, 2019 respectively and net cash flows of Rs. 96 lakhs for the six months ended September 30, 2019, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of net profit after tax of Rs. 2 lakhs and loss after tax (net) of Rs.1,086 lakhs for the three months and six months ended September 30, 2019 respectively and total comprehensive income of Rs. 1 lakh and total comprehensive loss of Rs. 1,057 lakhs for the three months and six months ended September 30, 2019 respectively, as considered in the Statement, in respect of 2 associates and 1 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
Firm's Registration No. 117366W/W-100018)



Vikas Bagaria  
Partner  
(Membership No. 060408)  
(UDIN: 19060408AAAABV5078)

Place: Mumbai  
Date: November 14, 2019